Back to Search Start Over

Molecular basis for selective activation of DREADD-based chemogenetics.

Authors :
Zhang S
Gumpper RH
Huang XP
Liu Y
Krumm BE
Cao C
Fay JF
Roth BL
Source :
Nature [Nature] 2022 Dec; Vol. 612 (7939), pp. 354-362. Date of Electronic Publication: 2022 Nov 30.
Publication Year :
2022

Abstract

Designer receptors exclusively activated by designer drugs (DREADDs) represent a powerful chemogenetic technology for the remote control of neuronal activity and cellular signalling <superscript>1-4</superscript> . The muscarinic receptor-based DREADDs are the most widely used chemogenetic tools in neuroscience research. The G <subscript>q</subscript> -coupled DREADD (hM3Dq) is used to enhance neuronal activity, whereas the G <subscript>i/o</subscript> -coupled DREADD (hM4Di) is utilized to inhibit neuronal activity <superscript>5</superscript> . Here we report four DREADD-related cryogenic electron microscopy high-resolution structures: a hM3Dq-miniG <subscript>q</subscript> complex and a hM4Di-miniG <subscript>o</subscript> complex bound to deschloroclozapine; a hM3Dq-miniG <subscript>q</subscript> complex bound to clozapine-N-oxide; and a hM3R-miniG <subscript>q</subscript> complex bound to iperoxo. Complemented with mutagenesis, functional and computational simulation data, our structures reveal key details of the recognition of DREADD chemogenetic actuators and the molecular basis for activation. These findings should accelerate the structure-guided discovery of next-generation chemogenetic tools.<br /> (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)

Subjects

Subjects :
Neurosciences

Details

Language :
English
ISSN :
1476-4687
Volume :
612
Issue :
7939
Database :
MEDLINE
Journal :
Nature
Publication Type :
Academic Journal
Accession number :
36450989
Full Text :
https://doi.org/10.1038/s41586-022-05489-0